A Phase I, Open-Label, Multicentre study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of Ascending Doses of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with MEDI4736 in Patients with Advanced Solid Tumours - Stand Up To Cancer

Blog

Posted October 11, 2019

A Phase I, Open-Label, Multicentre study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of Ascending Doses of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with MEDI4736 in Patients with Advanced Solid Tumours

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.